Company
South San Francisco
Every investor coverage indicates participated in a round Blade Therapeutics raised.
Companies Blade Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Gary Patou | Chief Medical Officer | OneVentures portfolio |
| Jim Scopa | Director | OneVentures portfolio |
| Luke Evnin | Chairman of the Board (former) | OneVentures portfolio |
| Mark Timney | Chairman of the Board | OneVentures portfolio |
| Wendye Robbins | President and Chief Executive Officer | OneVentures portfolio (Wed 12 Aug 2020), OneVentures portfolio (Mon 10 Aug 2020) |
Stories naming Blade Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Blade Therapeutics reports its Phase 2 trial of BLD-2660 in COVID-19 pneumonia has enrolled half its 120-patient goal, with full enrollment expected in the third quarter of 2020.
Blade Therapeutics appoints Mark Timney as board chairman, succeeding co-founder Luke Evnin; the release recalls its roughly $90 million raised from investors including OneVentures and The Medicines Company's $9.7 billion sale to Novartis.
OneVentures appoints Jim Scopa and Dan Baker to its healthcare investment team, and recalls its Healthcare Fund III backing Blade Therapeutics and BiVACOR.